The identification of growth factors that stimulate the proliferation and m
aturation of hematologic cells has been a major advance in the fields of he
matology and oncology. Production of these growth factors for clinical use
has had a significant impact in these and other fields by reducing the morb
idity and mortality associated with diseases and treatments. Availability o
f these growth factors has also expanded the treatment options for many pat
ients, particularly those with malignant neoplasms. Furthermore, the use of
hematopoietic growth factors has resulted in improved quality of life for
many patients.